Trial · NCT01494532
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period | Treatment Group A: Placebo | -1.91 | 95% Confidence Interval -2.46 to -1.35 | Hours | |
| Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period | Treatment Group B: 4 mg/Day | -2.04 | 95% Confidence Interval -3.02 to -1.06 | Hours | |
| Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period | Treatment Group C: 8 mg/Day | -2.92 | 95% Confidence Interval -3.50 to -2.34 | Hours | |
| Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period | Treatment Group D: 12 mg/Day | -2.34 | 95% Confidence Interval -2.91 to -1.76 | Hours | |
| Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period | Treatment Group E: 16 mg/Day | -2.80 | 95% Confidence Interval -3.36 to -2.24 | Hours | |
| Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period | Treatment Group F: 24 mg/Day | -2.37 | 95% Confidence Interval -3.26 to -1.47 | Hours | |
| Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period | Treatment Group A: Placebo | 65.4 | 95% Confidence Interval 52.4 to 76.4 | percentage of participants | |
| Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period | Treatment Group B: 4 mg/Day | 68.0 | 95% Confidence Interval 46.6 to 83.8 | percentage of participants | |
| Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period | Treatment Group C: 8 mg/Day | 75.4 | 95% Confidence Interval 63.0 to 84.6 | percentage of participants | |
| Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period | Treatment Group D: 12 mg/Day | 64.3 | 95% Confidence Interval 50.8 to 75.8 | percentage of participants | |
| Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period | Treatment Group E: 16 mg/Day | 77.9 | 95% Confidence Interval 66.0 to 86.5 | percentage of participants | |
| Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period | Treatment Group F: 24 mg/Day | 72.0 | 95% Confidence Interval 51.1 to 86.4 | percentage of participants | |
| Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group A: Placebo | 72.1 | 95% Confidence Interval 59.5 to 82.0 | percentage of participants | |
| Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group B: 4 mg/Day | 70.1 | 95% Confidence Interval 48.6 to 85.4 | percentage of participants | |
| Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group C: 8 mg/Day | 80.6 | 95% Confidence Interval 68.7 to 88.7 | percentage of participants | |
| Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group D: 12 mg/Day | 73.5 | 95% Confidence Interval 59.6 to 83.9 | percentage of participants | |
| Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group E: 16 mg/Day | 83.2 | 95% Confidence Interval 72.1 to 90.5 | percentage of participants | |
| Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group F: 24 mg/Day | 81.4 | 95% Confidence Interval 62.3 to 92.0 | percentage of participants | |
| Percentage of Participants With a >=2 Hours Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group A: Placebo | 53.7 | 95% Confidence Interval 39.8 to 67.1 | percentage of participants | |
| Percentage of Participants With a >=2 Hours Reduction in Baseline Off Time at Week 4 of the Maintenance Period | Treatment Group B: 4 mg/Day | 45.6 | 95% Confidence Interval 26.8 to 65.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01494532/results